Y-mAbs Announces Data to be Presented at SIOP 2021
September 16, 2021 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of...
Y-mAbs Announces Priority Review of BLA for DANYELZA® (naxitamab-gqgk) in China
September 13, 2021 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”), NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs to Host Key Opinion Leader Webinar on DANYELZA® (naxitamab-gqgk) Frontline and HITS Data in High-Risk Neuroblastoma
September 10, 2021 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments
August 05, 2021 16:01 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs to Announce Second Quarter 2021 Financial and Operating Results on August 5, 2021
July 29, 2021 16:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended June...
Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China
July 06, 2021 08:37 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of...
Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Receives Positive Opinion on Orphan Medicinal Product Designation by EMA
June 25, 2021 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, June 25, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma
June 23, 2021 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, June 23, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Frontline Data for DANYELZA® (naxitamab-gqgk) in High-Risk Neuroblastoma
June 04, 2021 09:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Update on Omburtamab for DIPG
June 04, 2021 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...